D. Nigel Thomas, Ph.D.
Vice President, Clinical Operations

Dr. Thomas is Vice President, Clinical Operations with responsibility for clinical trial execution of all clinical-stage programs both in the U.S. and worldwide. Dr. Thomas joined Novavax in April 2011 as Executive Director, Clinical Operations. He was most recently the Clinical Operations Director at Iomai beginning in 2006 and through acquisition by Intercell AG. He has previously held a variety of clinical operation positions in the Biotechnology and CRO industry and was a MacArthur Foundation Postdoctoral Fellow at the National Institute of Mental Health. He has overseen numerous vaccine, drug and medical device clinical trials including global Phase 2 and Phase 3 clinical trials for vaccines. Dr. Thomas received his Bachelor of Science degree in Pathobiology with a minor in Chemistry and his Doctor of Philosophy in Biochemistry and Physiology from the University of Reading, United Kingdom.